All In Biotech

Drug Trial Radar · NCT07947134

A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5864399 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Selected Advanced Solid Tumours

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

155

Planned (sponsor's estimate)

Start

Nov 25, 2026

Primary completion

Nov 16, 2029

Study completion Dec 28, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate a new drug, GSK5864399, in adult participants with advanced solid tumours. The study will assess how well the drug works against cancer, how safe it is, how the body processes the drug, and its effect on the tumours.

Conditions

  • Solid Tumours

Interventions

  • GSK5864399Drug

    GSK5864399 will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 & 2: Number of participants with Adverse events (AEs) by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0Time frame: Up to approximately 155 weeks
  2. Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 155 weeks
  3. Part 1 & 2: Number of participants with changes in safety parametersTime frame: Up to approximately 155 weeks
  4. Part 1 & 2: Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) by severityTime frame: Up to approximately 155 weeks
  5. Part 1 & 2: Number of participants with AEs leading to dose modificationsTime frame: Up to approximately 155 weeks
  6. Part 1 & 2: Number of participants with a change from baseline in body weightTime frame: Up to approximately 155 weeks
  7. Part 1 & 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)Time frame: Up to approximately 155 weeks
  8. Part 1 & 2: Number of participants with a change from baseline in cardiac function: Electrocardiogram (ECG)Time frame: Up to approximately 155 weeks
  9. Part 1 & 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to approximately 155 weeks
  10. Part 2: Confirmed Objective Response Rate (cORR)Time frame: Up to approximately 155 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.